Publication | Closed Access

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

Hematological MalignancyOncologyRetrospective SurveyHematologyPathologyImmune Checkpoint InhibitorMedicineRadiation OncologyCancer ResearchRefractory Multiple MyelomaHealth Sciences